Swiss study tracks IBD Patients' Real-Life choices for vedolizumab
NCT ID NCT04989907
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study observed 92 adults with inflammatory bowel disease (Crohn's or ulcerative colitis) who were already receiving or starting vedolizumab. Researchers watched how patients and doctors chose between intravenous infusion or subcutaneous injection in everyday practice. The goal was to understand treatment patterns and reasons for switching or stopping, without testing any new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bauchzentrum INSELSPITAL, Universitatsspital Bern
Bern, 3010, Switzerland
-
Clarunis AG
Basel, 4002, Switzerland
-
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum
Bern, 3012, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Universitatsspital Zurich
Zurich, 8091, Switzerland
-
Zentrum fur Gastroenterologie und Hepatologie AG
Zurich, 8048, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vedolizumab
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.